secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-061933
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports Q3 FY2024 net loss $17.1M; sunRIZE Phase 3 enrolling, DME Phase 2 topline expected May 2024
--------------------------------------------------------------------------------

- Net loss $17.1M for Q3 FY2024 vs $15.7M YoY; cash and equivalents $81.6M (down from $118.4M in June 2023).
- sunRIZE Phase 3 for cHI (RZ358) enrolling; completion expected end-2024; topline data mid-2025.
- Completed in-vivo tox study in brown Norway rats at 40 mg/kg; no liver abnormalities; to submit to FDA summer 2024.
- DME Phase 2 (RZ402) completed dosing of 94 patients; topline results expected May 2024.
- FDA alignment for potential registrational study in tumor HI; 5 insulinoma patients treated under Expanded Access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924061933/0001104659-24-061933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924061933/tm2414592d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-061933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer